This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Three Oversold BioTechs for Tired Gamblers:

#2. Biogen (BIIB)

Cashtaggers buzzed Monday about this biotech winning FDA approval for a hemophilia B treatment. The company announced Friday that the FDA gave the go-ahead for its DNA-derived treatment to control bleeding episodes in patients who have trouble clotting.

The company, which has a $72.18 billion market cap, has many approved drugs, including treatments for multiple sclerosis, leukemia and non-Hodgkin's lymphoma. Last year, the company earned $2.1 billion, excluding some items, on $6.9 billion in sales.

Analysts have 20 Buy ratings and 8 holds on the stock, according to the Analyst Ratings Network. Consensus calls for a $317 price target. It currently trades at $305.12. Sentiment on the stock is 75% bullish, according to StockTwits' analytics.

One of the few good stocks to trade for today: $BIIB

-- Selwyn Duijvestijn (@Marktgevoel) Mar. 31 at 09:51 AM

#3. Gilead Sciences (GILD)

This biotech giant with a $108 billion market cap is down nearly 16% in the past month. And that, say cashtaggers, is a buying opportunity. The stock rose 2% this morning.

$GILD $CELG $BIIB $REGN $IBB all showing strength in the pre-market, on high vol too

-- Brandon (@brduke) Mar. 31 at 09:13 AM

Gilead is most often in the news regarding its Hepatitis C drug Sovaldi, which was approved in December last year. The drug costs $1,000 a day, which has raised the ire of some in Congress, but it can cure patients of the disease. Untreated, Hepatitis C can result in liver failure.

Sovaldi isn't Gilead's only blockbuster drug. It also makes treatments for HIV/AIDS, cystic fibrosis, the flu, macular degeneration, hypertension and cardiovascular disease. That's one reason why the company brought in $3.45 billion, excluding some items, on $11.2 billion in revenues last year.

Analysts have 24 buy ratings on the stock and 2 holds, according to the Analyst Ratings Network. Consensus price target is $88.92. The stock currently trades at $70.19. Sentiment on the name is 83% bullish, according to StockTwits' analytics.

$GILD @searchlight Calls working this morning. Good job. Conviction pays.

-- Swingman24 (@Swingman24) Mar. 31 at 10:11 AM

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PCYC $261.25 0.66%
IBB $335.27 0.00%
AAPL $118.88 0.00%
FB $105.74 0.00%
GOOG $748.28 0.00%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs